Olaparib in Patients With HRD Malignant Mesothelioma (NCT04515836)
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
🩺 Plain-English Summary (8th-Grade Level)
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Who can join: Review the eligibility criteria below.
Location: University of Chicago Medical Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Chicago Medical Center — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (773) 702-0360
Email: hkindler@medicine.bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mesothelioma
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma — Baltimore, Maryland
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Los Angeles, California
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma — Tampa, Florida
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer — San Francisco, California
- A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
Explore by condition: All Mesothelioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.